DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on June 19, 2008; DOI: 10.1124/dmd.108.021352


0090-9556/08/3609-1859-1868$20.00
DMD 36:1859-1868, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.021352v1
36/9/1859    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Garland, M.
Right arrow Articles by Stark, R. I.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garland, M.
Right arrow Articles by Stark, R. I.

Placental Transfer and Fetal Elimination of Morphine-3-β-glucuronide in the Pregnant Baboon

Marianne Garland, Kirsten M. Abildskov, Tung-wah Kiu, Salha S. Daniel, Piper Weldy, and Raymond I. Stark

Perinatal Research Laboratory, Division of Neonatology, Columbia University, New York, New York

The glucuronide metabolites of several widely used drugs are detected in fetal plasma after maternal drug administration. However, the disposition of these metabolites is poorly understood and clinical concerns have been raised about accumulation of active metabolites in the fetus. For this reason, morphine-3-β-glucuronide (M3G), an active metabolite of morphine, was studied to provide quantitative data on disposition. Maternal, fetal, and bidirectional placental clearances of M3G were measured in three pregnant baboons. During maternal infusion of M3G to steady-state, the glucuronide metabolite readily appeared in fetal plasma achieving a mean ± S.D. fetal-to-maternal concentration ratio of 0.79 ± 0.04. In paired maternal and fetal infusions, steady-state clearances were 53 ± 3 (maternal), 1.5 ± 0.5 (maternal-to-fetal), 2.6 ± 0.1 (fetal-to-maternal), and –0.70 ± 0.6 ml · min–1 (fetal). These clearance values support bidirectional transfer of M3G across the placenta and indicate negligible direct clearance from the fetus. The clearance of M3G across the placenta is more than 20-fold less than that of morphine. Despite this low index of permeability, placental transfer contributes significantly to the glucuronide pool in the fetus. Placental transfer emerges as the major clearance pathway for the glucuronide from the fetus and suggests a component of active efflux. What is more, the results do not support the concept of sequestration in the fetal intestine as a significant route of clearance. Together these results clarify the distribution and clearance of glucuronides in the pregnant primate and facilitate prediction of fetal exposure to active metabolites.


Address correspondence to: Dr. Marianne Garland, Columbia University, College of Physicians and Surgeons, 630 W. 168th Street, BB4-404, New York, NY 10032. E-mail: mg71{at}columbia.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.